Please select the option that best describes you:
How do you plan to use adjuvant denosumab in patients with hormone positive breast cancer given the survival advantage seen in the ABCSG-18 trial?
Do you look into their stage/risk to decide? Since patients can experience bone loss after stopping denosumab, how do you plan to discontinue?
Answer from: Medical Oncologist at Academic Institution
Both adjuvant denosumab at 60 mg SQ every 6 months and adjuvant zoledronic acid at 4 mg IV every 6 months are reasonable options to consider as part of adjuvant treatment in post-menopausal women and both have prospective data to show statistically significant but very small improvements in disease ...
Sign in or Register to read more